The 18 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 174.00, with a high estimate of 250.00 and a low estimate of 130.00. The median estimate represents a +33.24% increase from the last price of 130.59.
The current consensus among 18 polled investment analysts is to Buy stock in Intellia Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.85
Reporting Date Nov 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.